ArticleJournal of nanobiotechnology2021
Molecularly engineered carrier-free co-delivery nanoassembly for self-sensitized photothermal cancer therapy.
Article in Journal of nanobiotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Gambogic acid induces cell death via covalent binding with PRDX1 to regulate ER stress and autophagy.Chinese medicine · 2026Article
- Review
- Celastrol-loaded metal-phenolic nanozymes integrated microneedles with ROS scavenging and anti-inflammatory activities for psoriasis treatment.Asian journal of pharmaceutical sciences · 2025Article
- Emerging Nanoparticle-Based Diagnostics and Therapeutics for Cancer: Innovations and Challenges.Pharmaceutics · 2025Review
- Advances in Pure Drug Self-Assembled Nanosystems: A Novel Strategy for Combined Cancer Therapy.Pharmaceutics · 2025Review
- A FRET-based off-on AIE nanoprobe enables instant and stain-free detection of hypoxic niches in tumor sections.Theranostics · 2025Article
- Advances in mechanisms and challenges in clinical translation of synergistic nanomaterial-based therapies for melanoma.Frontiers in cell and developmental biology · 2025Review
- The Emerging Landscape for Combating Resistance Associated with Energy-Based Therapies via Nanomedicine.Advanced materials (Deerfield Beach, Fla.) · 2024Review
- Caged Polyprenylated Xanthones inDrug design, development and therapy · 2023Review
- PpIX/IR-820 Dual-Modal Therapeutic Agents for Enhanced PDT/PTT Synergistic Therapy in Cervical Cancer.ACS omega · 2022Article
- Chidamide stacked in magnetic polypyrrole nano-composites counter thermotolerance and metastasis for visualized cancer photothermal therapy.Drug delivery · 2022Article
- Porphyrin NanoMetal-Organic Frameworks as Cancer Theranostic Agents.Molecules (Basel, Switzerland) · 2022Review
- Carrier-free multifunctional nanomedicine for intraperitoneal disseminated ovarian cancer therapy.Journal of nanobiotechnology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundPhotothermal therapy (PTT) has been extensively investigated as a tumor-localizing therapeutic modality for neoplastic disorders. However, the hyperthermia effect of PTT is greatly restricted by the thermoresistance of tumor cells. Particularly, the compensatory expression of heat shock protein 90 (HSP90) has been found to significantly accelerate the thermal tolerance of tumor cells. Thus, a combination of HSP90 inhibitor and photothermal photosensitizer is expected to significantly enhance antitumor efficacy of PTT through hyperthermia sensitization. However, it remains challenging to precisely co-deliver two or more drugs into tumors.
methodsA carrier-free co-delivery nanoassembly of gambogic acid (GA, a HSP90 inhibitor) and DiR is ingeniously fabricated based on a facile and precise molecular co-assembly technique. The assembly mechanisms, photothermal conversion efficiency, laser-triggered drug release, cellular uptake, synergistic cytotoxicity of the nanoassembly are investigated in vitro. Furthermore, the pharmacokinetics, biodistribution and self-enhanced PTT efficacy were explored in vivo.
resultsThe nanoassembly presents multiple advantages throughout the whole drug delivery process, including carrier-free fabrication with good reproducibility, high drug co-loading efficiency with convenient dose adjustment, synchronous co-delivery of DiR and GA with long systemic circulation, as well as self-tracing tumor accumulation with efficient photothermal conversion. As expected, HSP90 inhibition-augmented PTT is observed in a 4T1 tumor BALB/c mice xenograft model.
conclusionOur study provides a novel and facile dual-drug co-assembly strategy for self-sensitized cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.